Scholarlink

<p>Developments in CAR-T&#xa0;cell therapy represent one of the most innovative research fields in oncology and have already reached clinical routine in the treatment of hematological tumors. Unfortunately, gliomas are among those tumors for which all immuno-oncological approaches, including CAR-T&#xa0;cell therapy, are least successful. However, it is to be expected that CAR-T&#xa0;cell therapy will continue to increase in precision and effectiveness in the next few years, which may also lead to a&#xa0;possible application in the treatment of primary brain tumors. The challenges of CAR-T&#xa0;cell therapy for primary brain tumors lie, in addition to the basic clarification of the application by overcoming the blood–brain barrier (intravenous/intrathecally/intratumoral), in the lack of presence/persistence and activity of CAR-T&#xa0;cells in the tumor tissue, the specific tumor heterogeneity, especially of gliomas, the pronounced immunosuppressive environment and the insufficient understanding of potential central nervous system toxicities. The development of new, specific tumor antigens and more specific and durable CAR-Ts may become very important in the treatment of brain tumors in the future.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Die Perspektive der CAR-T-Zelltherapie in der Behandlung von Gliomen

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月2日

查看全文
  • Stefan Oberndorfer,
  • Martin Wiesholzer

摘要

Developments in CAR-T cell therapy represent one of the most innovative research fields in oncology and have already reached clinical routine in the treatment of hematological tumors. Unfortunately, gliomas are among those tumors for which all immuno-oncological approaches, including CAR-T cell therapy, are least successful. However, it is to be expected that CAR-T cell therapy will continue to increase in precision and effectiveness in the next few years, which may also lead to a possible application in the treatment of primary brain tumors. The challenges of CAR-T cell therapy for primary brain tumors lie, in addition to the basic clarification of the application by overcoming the blood–brain barrier (intravenous/intrathecally/intratumoral), in the lack of presence/persistence and activity of CAR-T cells in the tumor tissue, the specific tumor heterogeneity, especially of gliomas, the pronounced immunosuppressive environment and the insufficient understanding of potential central nervous system toxicities. The development of new, specific tumor antigens and more specific and durable CAR-Ts may become very important in the treatment of brain tumors in the future.